Xortx Therapeutics Reports Q3 GAAP Earnings Per Share of -$0.21
Xortx Therapeutics (XRTX) has released its third-quarter financial results, reporting a GAAP earnings per share (EPS) loss of $0.21. The announcement provides a snapshot of the company's current profitability status as it continues its clinical or operational development. The report serves as a key indicator for investors monitoring the company's cash burn and fiscal management. While specific revenue figures were not detailed in the brief release, the EPS figure highlights the ongoing net losses being incurred by the therapeutics firm during this period.

Tickers: $XRTX